This 12-month phase 1/2a dose-escalation trial, which transplanted CNS10-NPC-GDNF unilaterally into the lumbar spinal cord of 18 patients with ALS, met the safety endpoint. Here, GDNF is linked to amyotrophic lateral sclerosis.